CASC

Cascadian Therapeutics Inc

A clinical-stage biopharmaceutical company that developed targeted small-molecule therapies for cancer, most notably tucatinib, an oral drug for HER2-positive breast cancer that later reached patients under the brand name Tukysa. It began life as Biomira, later renamed Oncothyreon, and in 2016 rebranded as Cascadian Therapeutics — a nod to the Cascade Mountains of the Pacific Northwest, where the company was based — to mark its shift away from cancer vaccines toward targeted drug development. In 2018 it was acquired by Seattle Genetics (now Seagen), which took over tucatinib's development.

No Schedule 13D or 13G filings recorded.